BRIEF published on 11/14/2024 at 19:05, 6 days 17 hours ago ABIONYX Pharma: Third quarter 2024 financial report Biotechnology Treasury Turnover Q3 2024 ABIONYX Pharma
BRIEF published on 11/14/2024 at 19:05, 6 days 17 hours ago ABIONYX Pharma : Bilan financier du troisième trimestre 2024 Chiffre D'affaires Biotechnologie Trésorerie ABIONYX Pharma T3 2024
PRESS RELEASE published on 11/14/2024 at 19:00, 6 days 17 hours ago Quarterly financial reporting / Third quarter financial report ABIONYX Pharma reports Q3 2024 revenue of €3.4m and cash position of €4.1m before IRIS Pharma's CIR receipt. General Meeting on November 28, 2024, at 2.00 pm CET Cash Position General Meeting Biotech Company ABIONYX Pharma Revenue Update
PRESS RELEASE published on 11/14/2024 at 19:00, 6 days 17 hours ago Information financière trimestrielle / Information financière du troisième trimestre ABIONYX Pharma communique son chiffre d'affaires et sa trésorerie du 3ème trimestre 2024. Retransmission de l'AGE le 28 novembre 2024 Chiffre D'affaires Trésorerie ABIONYX Pharma 3ème Trimestre 2024 Retransmission AGE
BRIEF published on 10/24/2024 at 19:35, 27 days 17 hours ago ABIONYX Pharma presents the results of the RACERS study ABIONYX Pharma CER-001 Brain Fog Kidney Week Neuroinflammation
BRIEF published on 10/24/2024 at 19:35, 27 days 17 hours ago ABIONYX Pharma présente les résultats de l'étude RACERS ABIONYX Pharma CER-001 Brain-fog Neuro-inflammation Kidney Week
PRESS RELEASE published on 10/24/2024 at 19:30, 27 days 17 hours ago Informations privilégiées / Autres communiqués ABIONYX Pharma présente les résultats cliniques de l'étude RACERS sur le brouillard cérébral et l'efficacité de CER-001 au congrès annuel 2024 de l'ASN. Nouvelles données sur la neuro-inflammation et les troubles cognitifs ASN ABIONYX Pharma CER-001 Brain-fog Étude RACERS
PRESS RELEASE published on 10/24/2024 at 19:30, 27 days 17 hours ago Inside Information / Other news releases ABIONYX Pharma's RACERS study on CER-001 shows positive impact on cognitive impairment in brain-fog patients, presenting new clinical results at ASN 2024 Annual Meeting. Potential treatment for neuroinflammation ABIONYX Pharma CER-001 Brain-fog Neuroinflammation RACERS Study
BRIEF published on 10/21/2024 at 20:05, 30 days 16 hours ago ABIONYX Pharma reçoit un avis favorable de l'EMA pour le CER-001 ABIONYX Pharma CER-001 EMA Déficience LCAT AMM
BRIEF published on 10/21/2024 at 20:05, 30 days 16 hours ago ABIONYX Pharma receives positive EMA opinion for CER-001 ABIONYX Pharma CER-001 EMA AMM LCAT Deficiency
Published on 11/21/2024 at 12:00, 39 minutes ago Alset AI Announces Full Repayment of $3.7 Million Secured Loan with Interest from Portfolio Company, Significantly Strengthening Balance Sheet
Published on 11/21/2024 at 12:00, 39 minutes ago Battery X Metals Commences Strategic Initiatives to Strengthen Balance Sheet
Published on 11/21/2024 at 11:30, 1 hour 9 minutes ago FireFox Trenching Returns More High-Grade Gold at the Mustajärvi Gold Project in Lapland, Finland
Published on 11/21/2024 at 10:03, 2 hours 36 minutes ago Pixotope Launches Revolutionary AI-Powered Graphics Integration Tool for Broadcast Industry
Published on 11/21/2024 at 10:00, 2 hours 39 minutes ago BluSky Carbon JV Entity BluMountain Enters into JV Partnership in Southeastern USA
Published on 11/21/2024 at 12:15, 24 minutes ago Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Published on 11/21/2024 at 11:30, 1 hour 9 minutes ago APONTIS PHARMA AG: Condition of Minimum Acceptance in Zentiva’s Voluntary Public Purchase Offer Waived
Published on 11/21/2024 at 11:01, 1 hour 38 minutes ago Original-Research: SMT Scharf AG (von Montega AG): Kaufen
Published on 11/21/2024 at 06:58, 5 hours 41 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 5 hours 41 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 5 hours 41 minutes ago Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 16 hours 32 minutes ago Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 17 hours 19 minutes ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
